Skip to Main content Skip to Navigation
Journal articles

Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects.

Abstract : Interleukin-6 (IL-6) is a major survival factor for multiple myeloma (MM) cells preventing apoptosis induced by dexamethasone (DEX) or chemotherapy. In all, 24 consecutive patients with MM in first-line therapy received DEX for 4 days, followed by melphalan (HDM: 140 mg/m2) and autologous stem cell transplantation (ASCT). The anti-IL-6 monoclonal antibody (mAb) (B-E8) was given till haematological recovery, starting 1 day before DEX. Results were historically compared to MM patients treated with HDM 140 and 200 mg/m2. Our results show (1) that B-E8 was able to fully neutralize IL-6 activity in vivo before and after HDM as shown by inhibition of C reactive protein (CRP) production; (2) no haematological toxicity; (3) a significant reduction of mucositis and fever; (4) a median event-free survival of 35 months and an overall survival of 68.2% at 5 years with a median follow-up of 72 months; and (5) the overall daily IL-6 production progressively increased on and after 7 days post-HDM, with the increased serum CRP levels. In the 5/24 patients with uncontrolled CRP production, a large IL-6 production was detected (320 microg/day) that could not possibly be neutralized by B-E8. These data show the feasibility to neutralize IL-6 in vivo with anti-IL-6 mAb in the context of HDM.
Document type :
Journal articles
Complete list of metadatas

Cited literature [48 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-00136072
Contributor : Monique Frei <>
Submitted on : Monday, March 19, 2007 - 11:25:15 AM
Last modification on : Friday, May 15, 2020 - 12:22:03 PM
Long-term archiving on: : Tuesday, April 6, 2010 - 10:21:50 PM

Identifiers

Collections

Citation

Jean-François Rossi, Nathalie Fegueux, Zhao Yang Lu, Eric Legouffe, Carole Exbrayat, et al.. Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects.. Bone Marrow Transplantation, Nature Publishing Group, 2005, 36 (9), pp.771-9. ⟨10.1038/sj.bmt.1705138⟩. ⟨inserm-00136072⟩

Share

Metrics

Record views

391

Files downloads

674